Mesoblast’s Ryoncil sales approach $100M in first year of launch
Mesoblast (NASDAQ:MESO), a global leader in allogeneic cellular medicines, has reported net sales of $30.3 million for its flagship product, Ryoncil (remestemcel-L-rknd), for the third fiscal quarter ended March 31, 2026.











